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INTRODUCTION
Most biological functions are mediated by protein-protein interactions (PPIs), often involving large protein surface areas and shallow binding interfaces that are not conducive to targeting with conventional drug-like small molecules. An alternative approach under intensive investigation is to downsize one of the interacting protein surfaces, often a helix, to a bioactive small peptide capable of functionally mimicking or antagonizing the PPI 1 .
Short peptide sequences do not form thermodynamically stable helices in water. However, amino acid variations based on known α-helical propensities 2 , together with incorporating helix constraints, can realise potent peptidic and peptidomimetic antagonists of PPIs 1, 3 , and some efficacious peptides have entered clinical trials 4 . The helix constraints pre-organise peptides in receptor-binding α-helical conformations 5 , with improved protein-binding affinities 6 , protease resistance [7] [8] and, in some cases, increased cellular uptake 6 . Lactam bridges have been shown to be the most effective constraints for inducing peptide α-helicity 9 . Appropriately placed constraints have been shown to induce helicity and compensate for loss of enthalpy and binding free energy normally associated with considerable truncation 5 .
They have been used in conjunction with peptide truncation to derive small helical peptides that penetrate cell membranes 10 . Helix constraints can therefore compensate for the loss of binding free energy, associated with shortening peptide sequences, by pre-organizing peptides to minimize the entropic penalty for rearranging to a protein-binding helical conformation 5 .
Activator Protein-1 (AP-1) is a dimeric transcription factor that is hyperactivated in tumourigenesis [11] [12] and therefore antagonism of its function represents a promising therapeutic strategy for a number of human cancers 13 . AP-1 consists of different sub-units that are assembled via a bZIP domain. This is composed of a DNA-binding basic region and a 'leucine zipper' region involving a supercoiled heterodimer region of Jun (cJun, JunB, JunD) and Fos (cFos, FosB-1 and 2, Fra-1 and 2) proteins 14 . The Jun-Fos coiled coil binding interface features pseudo-parallel alignments of α-helical segments of Jun and Fos that make contacts over the length of the helices 15 . This PPI is difficult to target with hydrophobic drug-like molecules due to the lack of well-defined hydrophobic pockets 16 and to the difficulty in discriminating between the two interacting helical segments of Jun and Fos proteins. Small molecules examined to date have lacked Jun/Fos specificity [17] [18] , which is essential given that some AP-1 compositions have been shown to be anti-oncogenic 12 .
AP-1 can be antagonised by cJun mutants that lack transactivation domains [19] [20] , by cJun and cFos mutants with truncated DNA-binding domains 21 , and by mutations in DNAbinding domains that then require an extended dimerisation interface 22 . These mutant peptides bind efficiently to Jun and, when expressed in cells, can inhibit AP-1 to cause cell cycle arrest and reduced cell proliferation [22] [23] [24] . However, such polypeptides are susceptible to degradation by proteases, do not permeate cell membranes, and have low bioavailability.
Here we investigate the possibility of deriving short helical peptides from the Jun-binding region of cFos, a protein consisting of 380 amino acid residues featuring a leucine zipper region for heterodimerisation with Jun, a basic region for binding to DNA, and a transactivation domain at its C-terminus. We report steps towards minimising the length of the Fos fragment, altering it using helix constraints to optimise Fos-Jun interactions, and modifying the peptides further for entering cancer cells and targeting AP-1 in the nucleus to inhibit proliferation. This minimalist approach using helix constraints is still an under-utilised strategy for modulating protein-protein interactions, but it is unclear whether it can be useful in producing effective antagonists of protein-protein interactions specifically involving coiled coils that tend to involve key interactions along their entire interface 25 .
RESULTS

Structure of FosW-Jun, a model protein-protein interface
We have previously used an intracellular protein-fragment complementation method 26 to derive a 37-residue peptide FosW 27 from a cFos-based library. This peptide was able to bind Jun and antagonise both Fos-Jun and Jun-Jun protein-protein interactions, but the structure of FosW-Jun is unknown. Here we have complexed FosW with Jun, obtained diffracting crystals, and determined a crystal structure to a resolution of 2.3 Å ( Figure 1 and Table S1 ) (PDB ID: 5fv8). This is the first crystal structure of an AP-1 antagonist in complex with its target, and importantly identifies the anticipated binding mode of FosW with Jun 26 .
Inspection of the crystal structure shows that FosW and Jun have bound together to form a parallel dimeric coiled coil, with characteristic hydrophobic interactions (a i -a' i and d id' i ) and electrostatic contacts (g i -e' i+7 and e i -g' i-7 ) (Figure 1 and Supplementary Information).
Consistent with other coiled coils 3 , all ten residues at positions a and d are appropriately aligned for burying hydrophobic side chains away from the water solvent. This confers a major energy contribution to dimerisation 28 , with interatomic distances consistent with important structure-stabilising interhelical a-a' and d-d' interactions 15, 29 . Thus our selection of predominantly bulky hydrophobic side chains to substitute at positions a of FosW has evidently improved sidechain packing in the core relative to cFos residues (TΔL, TΔI, KΔN and KΔL), thereby increasing enthalpy and driving dimerization.
Interactions between g1 E and e'2 K, and g3 E and e'4 R are potentially helixstabilising. Residues at g2, e'3, e3, g'2, e4 and g'3 are correctly positioned to make similar interhelical interactions, but are too far apart to form contacts. Finally, an anticipated e2g'1 E-K interaction is not present in the crystal structure; rather the g'1 K amine nitrogen faces away from the e2 E. The crystal structure indicates that g2 R interacts with solvent rather than with g3 E. The e4 E does not interact with g'3 T, but may shield FosW a4 I from solvent with its hydrocarbon chain. Similarly, e1 and g4 Q residues, which have no g' i-7 or e' i+7 partner, shield a2 I and d4 L core residues. Finally, we note that positions b, c and f are occupied by residues that are not significantly involved in interhelical interactions according to the crystal structure, instead appearing to be involved in solvent interaction for solubility.
Possible exceptions may be intrahelical interactions, such as a proposed salt bridge between f3 K and b4 E, with attraction of f4 K towards the b4 E and a cation-π attraction between b3 Y and f3 K. The contributions of these intrahelical interactions to α-helix adoption and dimerisation free energies are, however, expected to be small. As such, FosW b, c and f positions may tolerate replacement residues that form helix constraints without significantly affecting the PPI interface 26 .
Jun is predicted to be a more attractive target than Fos because of a more typical and hydrophobic interface at a and d positions of the Jun heptads ( Figure 1 ) compared to the polar T/K-containing Fos core [26] [27] . As a consequence, Fos is reported to be unable to form homodimers, and requires Jun family members to form transcriptionally active heterodimers 30 . Complexes containing Jun are also more potent for transcriptional transactivation 30 , and Jun has been implicated in a number of cancers [11] [12] , making antagonists of this particular homologue potentially valuable. Therefore, we have concentrated here on downsizing Fos rather than Jun to create antagonists of the Fos-Jun protein-protein interaction.
Downsizing FosW via helix-inducing constraints
The major aim was to introduce one or more helix-inducing constraints into the FosW sequence to enable downsizing of the molecule while maintaining helicity and ultimately affinity for cJun. All helix-constrained peptides lacked five residues that served as N-terminal and C-terminal capping motifs within the FosW parent peptide. This led us to iteratively examine the effect on helix induction and affinity using one or more such constraints placed at different positions within the sequence, while concomitantly truncating the sequence from either terminus (see Figure 2 In an effort to restore binding affinity, the sequence length was extended to 29 residues. Compounds were truncated from the N-terminus and lactam bridges inserted at positions 7-11 and 29-33 (18), or 11-15 and 29-33 (19) . These compounds had significant binding affinity (K d = 56 nM and 100 nM) and helicity (72 % and 64 %). Subsequent truncation from the N-terminus of 19 to 25 residues gave compound 20 with higher affinity (K d 2 μM) and alpha helicity (85 %) ( Figure S1 ).
Having identified some shorter peptides, isothermal titration calorimetry (ITC) ( Figure 3 and Figure S2 ) was used to assess enthalpic and entropic energy contributions to binding to Jun (Table 1) . Compounds 14 and 15 had the highest negative entropy of binding (TΔS = -5.7 and -5.2 kcal per mol), while peptides 18-20 had improved ΔG retention. The 25mer peptide 20 retained substantial binding free energy through entropic gain and was a good compromise between shortening the sequence (reducing enthalpy) and constraining the helix (increasing entropy).
Helicity is expected to be an important contributor to binding affinity 2, 5 . Interacting peptides had homomeric helicities ≥ 39 % with a mean helicity (63 %) substantially higher than for FosW (41 %), whilst non-interacting peptides had a mean helicity of 37 %, close to that of FosW. When mixed with Jun, interacting peptides had heteromeric helicities ≥44 % with a mean helicity (55 %), much higher than FosW-Jun (37 %), whilst non-interacting peptides had a mean helicity of 26 %. However, contrary to expectations, there were no strong relationships between helicity, affinity and entropy beyond these qualitative thresholds (See Supplementary Information).
Peptide 20 binds Jun effectively via entropic pre-organisation
Peptide 20 consists of a NΔ9CΔ3 peptide (loss of 9 residues from the N-terminus and 3 from the C-terminus relative to FosW; Figure 2 ) and can make 8 a/d and 2 e/g favourable interactions with Jun, compared with 10 a/d and 3 e/g favourable interactions for FosW binding to Jun. It also produced coiled coils with Jun that were much more helical (62 %) than FosW-Jun (37 %) ( Figure 3 ). The increased helicity can be attributed to the two helix constraints positioned at the N-and C-terminus. Therefore despite truncation of one-third of the sequence relative to FosW, significant binding energy was maintained. Furthermore, 20 displayed the expected entropy benefit conferred by the two helix constraints, a significant gain of +3.2 ± 0.5 kcal/mol to TΔS compared to FosW-Jun ( Figure 3 
Development of cell permeable compounds
Compounds 18 (29 residues) and 20 (25 residues) were identified as compromises between truncating the peptide sequence and retaining some of the affinity observed for FosW (37 residues) binding to Jun. To investigate whether these peptides would enter cells, fluorescein isothiocyanate (FITC) was coupled to their N-terminus via a flexible linker (6- aminohexanoic acid) to allow detection via flow cytometry and live cell confocal microscopy.
There was negligible uptake of either FITC-18 or FITC-20 into MCF-7 breast cancer cells after 1 h or 6 h ( Figure 4B ). Thus, further modification of these peptides to promote cell uptake or penetration was needed if these compounds were to exhibit biological activity in cells. Three strategies were investigated for delivering these helix-constrained peptides into cells: attaching a lipid, appending a cell penetrating peptide (CPP) sequence, or replacing the polar helix-constraining lactam bridges with more hydrophobic helix-constraining hydrocarbon linkers.
Firstly, palmitic acid was conjugated to the N-terminus of peptide 20 to give Pal-20, anticipated to interact with the lipid bilayer to enhance uptake 31 . However, the conjugate showed no significant binding to Jun, as measured by CD or ITC techniques. Secondly, the first ten residues of cationic cell penetrating peptide sequence TAT derived from HIV-1 32 was attached to the C-terminus of 20 to give 20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , but this is only known to enhance peptide uptake into the cytoplasm, not the nucleus. An additional nuclear localisation signal sequence from the SV40 large T-cell antigen 33 was therefore also appended to produce 20-NLS-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , for the purpose of both enhancing cell uptake and directing 20 to the nucleus.
These peptide appendages did not significantly affect binding affinity for Jun, and a positive TΔS term was maintained ( Table 1 ). The third strategy involved replacing the lactam bridges in compounds 18 and 20 with more hydrophobic hydrocarbon bridges to give 18-HC and 20-HC, which was found to reduce binding affinity for Jun (K d 320 nM and 15 µM, respectively) but maintain a positive TΔS term (Table 1) .
Cell uptake was monitored by flow cytometry using FITC labelled analogues of 18HC, 20HC, 20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and 20-NLS-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] (Figure 4B ). 20-NLS-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] showed the highest cell uptake with the most fluorescence at 1h and 6 h, comparable to FITC-labelled TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] alone.
Cells incubated with 20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] displayed increased levels of fluorescence at 6h, whilst 18HC and 20HC had comparable levels of cell uptake after 6 h. We next analysed these peptides by live cell confocal microscopy to observe how these compounds were distributed throughout the cell. FITC-18HC and FITC-20HC localised differently within MCF-7 cells. FITC-18HC was freely distributed throughout the cytosol and the nucleus, whereas FITC-20HC was mainly trapped within endosomes or aggregated within the cell ( Figure 4B ), possibly owing to a change in the net charge of the protein (-4 vs -2). TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] (FITC-20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] showed cytosolic uptake and a small amount of nuclear localisation. However, addition of the nuclear localisation signal (FITC-20-NLS-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] ) promoted very efficient cellular uptake and led to much greater nuclear localisation. All four compounds were distributed differently in the cells, potentially impacting on their biological properties.
Antiproliferative activity in human breast cancer cells
Both MCF-7 and ZR75-1 are breast cancer cell lines that are dependent on AP-1 activity for proliferation [34] [35] . Having demonstrated that C-terminal appendage of cationic cell penetrating peptides was sufficient to facilitate efficient cellular uptake and nuclear localisation of 20, or alternatively that hydrocarbon staples were sufficient to facilitate cell uptake and nuclear localisation of 18, we next sought to investigate whether these peptides inhibited cell proliferation. Treatment with 20, 20HC, 18 or 18HC did not affect proliferation of MCF-7 or ZR75-1 cells at the concentrations tested ( Figure 4C, 4D ). However, 20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] did significantly reduce proliferation of both MCF-7 (83 % reduction) and ZR75-1 cells (70 % reduction) at 30 μM, while 20-NLS-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] at the same concentration reduced proliferation to an even greater extent (95 % and 96 % respectively, Figure 4D ). Neither TAT 48-57 nor NLS-TAT 48-57 alone at the same concentration reduced cell viability ( Figure 4C, 4D) , and no peptide showed any haemolytic activity on red blood cells after six hours at peptide concentrations up to 30 μM, indicating that cell viability was not inhibited by the peptides through non-specific membrane disruption (Table S2 ).
These results indicate that our successful strategy of downsizing Fos to helixconstrained short peptides has overcome the energy barrier to binding Jun. The next hurdle was to modify the short peptide antagonists for cell uptake and nuclear localisation. Cell uptake was achieved by making the helix constraints more hydrophobic, but a nuclear localisation signal was still required to access the intracellular target of Fos peptides and affect proliferation of AP-1 containing breast cancer cells. These important steps taken here to target the Fos-Jun binding interface provide a valuable platform for further development of Fos-derived small molecules as AP-1 inhibitors in cancer therapy.
DISCUSSION
Helix constraints confer affinity to cFos peptides enabling their shortening
The 37-residue truncated analogue of cFos (FosW) has been crystallised here in complex with a Jun peptide. FosW is an antagonist of the interaction of Jun with Fos 26 . The crystal structure of FosW-Jun has identified the relative positioning of amino acid sidechains in FosW and Jun and their specific involvement in inter-helix interactions that stabilise the heterodimer in a coiled-coil complex (Figure 1) . The structure provides valuable information as to the optimal sites for modifying Fos without disrupting interhelical interactions.
Nevertheless, truncating this peptide was found to substantially attenuate binding affinity for Jun, due principally to loss of binding enthalpy, as demonstrated by the linear counterpart of 20 (LIN20) ( Table 1 ). To compensate for this loss of enthalpy upon truncating the FosW sequence, we have investigated the effect of incorporating one, two or three helix-inducing (i→i+4) lactam bridges at positions in FosW away from the helix-helix binding interface with Jun. These constraints were anticipated to reduce the conformational entropic penalty for helix formation 36 . Promotion of helicity was anticipated to improve binding affinity for Jun, which is dependent on a supercoiling event between helical partners 2, 37-38 . By increasing helicity in truncated FosW analogues, we anticipated reducing the entropic penalty associated with pre-organising the shortened helix for target binding, a strategy used successfully to enable downsizing of other α-helical partners in proteinprotein interactions [5] [6] 39 .
Lactam helix-inducing constraints at (i→i+4) positions were chosen due to their ability to impart greater alpha helicity per residue relative to other linkers, such as hydrocarbons, triazoles, m-xylene thioether and alkyl thioether 9 , and due to the simplicity and minimal sequence disturbance of merely connecting amino acid sidechains to form lactams. Positioning these cyclic pentapeptide motifs within the FosW sequence induced substantial α-helicity (60-77 %) relative to the linear sequence, despite significant shortening. However, we find here that high helicity alone in Fos peptide analogues does not guarantee high affinity for Jun (See Supplementary Information) , reinforcing the importance of sequence in coiled coil formation and stability. The use of helix constraints was anticipated to permit at least some truncation of the FosW sequence without loss of Jun binding. Indeed, truncation from either terminus coupled with careful positioning of the helix-inducing constraints between non-interfacial b, c and f residues, particularly at peptide termini, has successfully enabled identification of truncated peptides which maintain both high helicity and affinity for Jun (Figure 2, 3 ).
Compounds 18 (29 residues, K d 56 nM) and 20 (25 residues, K d 2 µM) were identified as compromises between shortening the peptide sequence (22 % and 33 %, respectively) relative to FosW and retaining some of the affinity observed for FosW (37 residues) binding to Jun. Additionally, 18 and 20 retained high helicity (69 % and 62 %, respectively) when bound to Jun (15 % helical in isolation 27 ), compared with 72% and 85% in isolation (i.e. homodimeric -see Figure S2 ). For 20 there was a clear entropic gain that contributed to the favourable interaction free energy, and this partially compensated for a loss in binding enthalpy. Conversely, LIN20 suffered the same enthalpic loss as 20 (within 1.1 kcal/mol), but without constraints there was no entropy gain, and so ΔG was reduced by 43 % compared to FosW. The helix-inducing constraints in 20 therefore provide 19 % of the free energy of binding compared to the unconstrained peptide, translating to a 27-fold improvement in affinity for Jun. This finding demonstrates the value of helix-inducing constraints in truncated peptides for maintaining significant bioactivity. These two peptides show greater ligand efficiency (ΔG per unit molecular weight), higher entropy gain, and greater water solubility than similar length analogues, 14 and 15. Peptides 20 and 18 were therefore chosen for the next stage, the testing of cellular uptake and functional activity.
Helicity, entropic stabilisation and binding affinity
Helix-inducing constraints are expected to confer an entropy advantage by preorganising peptides in the helix-binding conformation preferred by the target. Molecules with greater helicity might better form coiled-coils 5, 37-38 , however we find this to be an over-simplification. For the case of a coiled coil, there is likely a limit to the entropy value of pre-organising a helical structure. Above a certain threshold helicity, conformational entropy may oppose coiled-coil formation 27 , perhaps reflecting a need for flexibility in a helix to enable some distortion necessary for supercoiling [40] [41] . A key issue with a coiled-coil is that there is usually a fairly even contribution of residues along the entire coil to the binding energy, with fewer hot spots localised in a single region of the sequence that can form the basis for truncation. It is notable that truncation to 20 results in substantial loss of enthalpy, consistent with enthalpy contributions from residues all along the coiled coil 5 .
This may prevent further antagonist truncation, requiring innovation to increase both entropy and enthalpy through unnatural amino acid replacements that still enable coiled coil formation. Consequently, very few short helical antagonists of coiled coil PPIs have been described in the literature to date 25 .
Cell uptake and nuclear localisation
AP-1 is localised in the cell nucleus, so the development of Fos-derived peptides that can antagonise Fos-Jun binding is only the first step towards drugs that can modulate AP-1 in vivo. The unconstrained and polar FosW peptide antagonist of Jun-Fos binding has low conformational stability, high susceptibility to degradation by proteases in blood and in cells, and poor permeability across cell membranes. Helix constraints have been found to improve all of these properties for some peptides [5] [6] . However, cellular uptake is difficult to predict. It is highly dependent on the peptide sequence, the type of helix constraint, and the cell type 42 .
Given the size of our short FosW-derived peptides compared to cellular Jun and Fos proteins, it was our aim to assess their ability to compete with these for an interaction with Jun inside the cell. We chose 20 for assessment of cellular uptake and nuclear localisation because of its higher affinity (K d 2 μM) compared to the shortest Jun-derived antagonist of Jun-Fos interactions (K d 7.3 μM) reported previously 5 , and the greater expected value of Fos-peptides as antagonists against oncogenic Jun [11] [12] 30 than for Jun-peptides against cFos 5 . While lactam-bridges were very effective as helix-inducing constraints in FosW-derivative peptides, there was no evidence for cell internalisation of 20. Previous reports of the cell penetrating potential of hydrocarbon constrained peptides 42 encouraged the synthesis of the analogue FITC-20HC. While that peptide did pentrate cells, it did not display favourable intracellular distribution for AP-1 targeting. The longer peptide analogue 18HC, which also had higher affinity for Jun than 20HC, was also generated to compare cellular uptake and activity. Cell uptake did increase, but there was little uptake into the nucleus and consequently the peptide concentration may not have been high enough for AP-1 inhibition.
We therefore added TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] or a NLS-TAT 48-57 appendage to help drive higher cell uptake and target more 20 to the cell nucleus where AP-1 is active (Figure 4 ). TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] increased uptake and favourable distribution, which further increased with additional inclusion of the NLS sequence (Figure 4 ). Considering the minimal concentrations (µM) known to be required for internalisation of cationic CPP conjugates 43 , these conjugates of 20 were considered to have been delivered at a minimum effective concentration. Cytoplasmic cotranslational/post-translational sequestration of Jun before nuclear transport may also be desirable to expedite Jun degradation by cytoplasmic ubiquitin/proteasomal pathways.
Thus, the improved nuclear and cytosolic presence of 20-NLS-TAT 48-57 over 20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] was considered to be promising for AP-1 inhibition.
Antiproliferative activity of 18 and 20 in breast cancer cells
AP-1 is known to be overexpressed in many breast cancers 44 , where it drives tumour initiation and development 45 , and thus is an important target for cancer therapy. MCF-7 and ZR75-1 breast cancer cells are dependent on AP-1 for expression of a variety of genes in response to pro-oncogenic growth factors 34 , including extracellular matrix metalloproteinase MMP9 [46] [47] and G1→S phase regulator Cyclin D1 24, 35 , such that reduced metastatic potential and cancer cell proliferation results from repression of these genes.
Poor uptake, endosomal trapping and/or aggregation, and low Jun binding affinity may have prevented 20HC from affecting cell viability, whilst poorly internalised 18HC also did not reduce cancer cell viability despite apparently avoiding endosomal trapping or aggregation (Figure4B). However, conjugation of both TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and the SV40 NLS to 20 led to significant reduction in the viability of both MCF-7 and ZR75-1 breast cancer cells. This suggests that cell and nuclear penetration were the limiting factors for AP-1 inhibition by 20 since TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and NLS appendages alone had no effect on cell viability and non-specific cell lysis was negligible. Thus, we have demonstrated that once sufficiently internalised into the cell nucleus, 20 displays significant inhibition of AP-1-driven oncogenesis. Moreover, once internalised the CPP component of the peptide is predicted to expendable, without significant effect on the activity of 20.
CONCLUSION
The strategy of iterative sequence truncation, coupled with insertion of helixinducing constraints at appropriate positions, was used to reduce the size of Fos to peptide fragments as antagonists of Fos-Jun coiled coil formation. The first crystal structure of an AP-1 antagonist, a Fos-derived peptide complexed with Jun, was used to design helixconstrained and truncated peptides that similarly bound to Jun. Several rounds of iteration led to peptides 18 and 20, which were efficient Jun-binding ligands relative to their size and were able to inhibit the Fos-Jun interaction. Compounds 18 and 20 represented compromises between downsizing to a minimal binding sequence and retaining appreciable binding affinity for Jun. Isothermal titration calorimetry measurements revealed that the helix-inducing constraint provided an entropic advantage for binding to Jun relative to analogous unstructured short peptides. Importantly, the cell penetrating peptide TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] together with the nuclear localisation signal peptide SV40, or alternatively a hydrocarbon (i→i+4) helix-constraining linker, enabled substantial cell uptake and delivery of 18 and 20
into the nucleus of cells where AP-1 is active. With these adaptations, compound 20 was able to both enter the nucleus of cancer cells and reduce their proliferation in vitro at low µM concentrations. This potency compares favourably with small molecule AP-1 inhibitors such as momordin I (IC 50 ≈ 30 μM) and T-5524 (IC 50 ≈ 10 μM) that have reached clinical trials 18, 48 . Compound 20 represents one of few examples to date of a helix-constrained peptide that can modulate a PPI featuring coiled-coil peptides 25, 42 . The approach highlighted here, using helix-inducing constraints to compensate for shortening the sequence of a binding partner in a coiled coil transcription factor, shows considerable promise. Further development of Jun antagonists based on truncating Fos is required to generate useful AP-1 inhibitors suitable for treating cancers featuring AP-1 dysregulation.
METHODS
Circular Dichroism (CD spectra and thermal melts)
Coiled coil stability was analysed as previously described 5 using a Chirascan (Applied Photophysics) instrument, recording ellipticity of homotypic (peptide) or heterotypic (1:1 peptide:Jun stoichiometric mix) samples at a total peptide concentration (P t ) of 150 μM, dissolved in 10 mM potassium phosphate buffer with 100 mM potassium fluoride, pH 7.
Isothermal titration calorimetry (ITC)
Coiled coil interaction thermodynamics were assessed as previously described 5 using a Microcal VP-ITC instrument (GE Healthcare). Jun at 100 μM -3 mM was injected into peptide homotypic samples at 9 μM -200 μM in circular dichroism buffer.
SUPPORTING INFORMATION
Peptide characterisation, Peptide synthesis and purification, CD measurements and fitting procedures, ITC measurements and fitting procedures, X-ray crystallography procedures (Table S1) , Cell culture and assays, Live Cell Confocal Microscopy, Flow Cytometry, Cell Viability, Peptide haemolytic activity (Table S2) 49 . Constraint of all heptads except Heptad 3 generated full length peptides (minus AS and GAP capping motifs) with similar dissociation constants to that of FosW but improved helicity, whist addition of a second constraint was generally effective in inducing further increased helicity, and even lower dissociation constants. Truncations from N-and Ctermini were effective if combined with optimal positioning of constraints. ITC experiments not performed because binding measured by CD was negligible are labelled "ND" ("not determined"). ITC experiments that generated binding too weak for accurate fitting are labelled "NF" ("not fit"). Worrall and Mason (2011) . CD values are taken from representative single measurements, which are typically reproducible in biological replicates to ± 1 °C for T m , within 5 % for fractional helicity and 222:208 ratio (θ 222 / 208 ), and within 10 % for K d and ∆G (data not shown). ITC values are the arithmetic mean of at least two independent titrations ± SDs, except values from Worrall and Mason (2011) indicated with an asterisk and values for 20-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and 20-NLS-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] (single titrations and fitting errors). CD and ITC data generally agree to within 15 % for ΔG and an order of magnitude for K d . ITC experiments not performed because binding measured by CD was negligible are labelled "ND" ("not determined"). CD or ITC experiments that generated binding too weak for accurate fitting are labelled "NF" ("not fit"). 
